Study identifier:D9612N00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A cohort study on the association between acid-suppressing drugs in pregnancy and asthma in the offspring
Asthma in offspring
N/A
No
Risk of asthma in offspring
Female
10116
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2015 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
All women exposed to PPI at any time during pregnancy Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date | Drug: Risk of asthma in offspring Exposure to PPI or H2RA, respectively during pregnancy No exposure to acid suppressing drugs during pregnancy |
All women exposed to H2RA at any time during pregnancy Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date | Drug: Risk of asthma in offspring Exposure to PPI or H2RA, respectively during pregnancy No exposure to acid suppressing drugs during pregnancy |
Pregnant women with no recorded use of acid suppressing drugs Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy | - |